Overview

Gender

male

Investor Type

Investment Partner

Mark Gudiksen joined TPG Biotechnology in 2008, with a focus on both healthcare and industrial biotechnology. Prior to joining TPG Biotechnology, Mark Gudiksen was at McKinsey & Company where he worked on a broad spectrum of strategic topics and M&A opportunities.

Prior to this, Mark Gudiksen received his Ph.D. in chemical physics from Harvard, and his B.S. in chemistry from Stanford.

His doctoral work in nanotechnology was recognized with several highly cited publications in leading scientific journals, such as Science and Nature, as well as general audience publications as broad as Scientific American and the Wall Street Journal.


Mark Gudiksen currently serves on the boards of directors of Alphabet Energy, Inc., Auxogyn, Inc. and Nodality, Inc., and is a board observer at DNAnexus, Inc.